Up-Front Milestone Balance Shifting in Biotechs' Favor Aug. 29, 2011 By Brian Orelli For years, biotechs seeking to out-license their drug candidates have had to retain an increasing portion of the development risk.Read More
Products, FDA Clarity Draw Pharma Back to Antibiotics Aug. 8, 2011 By Brian Orelli It seems big pharma may be coming back to antibiotics, a treatment area they previously left for dead.Read More
